TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06754852: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

Sponsor: Hemab ApS · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 108 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$5,220,700

Rescue Site Savings

+$3,442,840

Unlock Full NCT06754852 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06754852 Rescue Dossier →